Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2025-06-30 AGM Information
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
Immediate Report
AGM Information Classification · 98% confidence The document explicitly states it contains the "Results of the Company’s Annual General Meeting of Shareholders". This directly corresponds to the definition of AGM Information. Furthermore, the document is short (1937 chars) and mentions an attached report (*FORM_6-K_30-Jun-25_isa.pdf*), which suggests it is an announcement related to the AGM results rather than the full presentation itself. However, since the core subject is the AGM results, AGM-R is the most specific classification. If the document were purely an announcement stating the results were published elsewhere without detailing the results, RPA might be considered, but here the title implies the results are the subject matter being reported via the 6-K filing structure.
2025-06-30 English
6-K
Regulatory Filings
2025-06-30 English
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
Regulatory Filings Classification · 96% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION' as a 'REPORT OF FOREIGN PRIVATE ISSUER'. Form 6-K is used by foreign private issuers to report material information that is made public in their home country or that is required to be filed with a foreign securities exchange. This type of filing is generally used for current reports, similar to 8-K filings in the US, and often contains press releases or material updates. The content is a press release announcing clinical trial data updates and a presentation schedule for an upcoming medical conference (ASCO 2025). Since Form 6-K is a general current report for foreign issuers and does not map directly to the specific US forms like 10-K (Annual Report) or 10-Q (Quarterly Report), it falls under the category of general regulatory filings or current material event reporting. Given the provided options, 'Regulatory Filings' (RNS) is the most appropriate general category for a Form 6-K that is not an annual report, interim report, or specific announcement like dividend/insider trading. However, since the document is a formal SEC filing (Form 6-K) containing material information, and the content is a press release about clinical data, it is a current report. In many classification schemes, Form 6-K maps best to a general regulatory filing category. If the content were purely an Earnings Release (ER) or an Investor Presentation (IP), those codes might apply, but the wrapper is the Form 6-K itself. Given the options, RNS (Regulatory Filings) serves as the best fit for a non-standard, current SEC filing like a 6-K that isn't covered by other specific codes.
2025-05-30 English
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting* *6-K_30-May-25_isa.pdf*'. The document itself is very short (2031 characters) and serves primarily to announce the publication of an attached report (a 6-K filing, which is often used by foreign private issuers for material events). According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA). Since this is an announcement of a material event/report, RPA is the most appropriate classification over the general fallback RNS.
2025-05-30 English
6-K
Regulatory Filings
2025-05-30 English
6-K
Regulatory Filings
2025-05-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.